Monte Rosa Therapeutics
🇺🇸United States
First-in-human Study of MRT-6160 in Healthy Subjects
Phase 1
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- Drug: MRT-6160Drug: Placebo
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Monte Rosa Therapeutics, Inc
- Target Recruit Count
- 76
- Registration Number
- NCT06597799
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Study of Oral MRT-2359 in Selected Cancer Patients
Phase 1
Recruiting
- Conditions
- NSCLCProstate CancerHR-positive, HER2-negative Breast CancerDLBCLL-MYC and N-MYC Amplified Solid TumorsSCLCHigh Grade Neuroendocrine CancerNSCLC With High or Low L-MYC or N-MYC Expression
- Interventions
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Monte Rosa Therapeutics, Inc
- Target Recruit Count
- 174
- Registration Number
- NCT05546268
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸University of California San Diego, San Diego, California, United States
© Copyright 2025. All Rights Reserved by MedPath